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INTRODUCTION: 
The medication class of thiazolidinediones (TZDs; also 
called as “glitziness”) was introduced in late 1990’s as an 
adjunct therapy for type II diabetes mellitus and related 
diseases. Thiazolidinediones bind to the gamma form of 
the peroxisome proliferators activated receptor (PPARˠ ). 
This stimulates peripheral adiposities to increase their 
uptake of free fatty acids, which leads to reduction in the 
fat stored in muscles, liver and visceral fat deposits. The 
TZDs also leads to an increase in the secretion of 
adiponectin and a decrease in the production of resistin and 
tumor necrosis factor α (TNF-α). It is unknown if TZDs 
have direct effect on muscles or liver.
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Figure.1: Mechanism of action of 2, 4-thiazolidinedione 
ABSTARCT: 
The research work was carried out to evaluate the antioxidant activity of derivatives of 2, 4-thiazolidinedione (ISS-1, ISS-2, 
ISS-3, ISS-4, and ISS-5). Thiazolidinedione are synthetic agonists for the transcription factor peroxisome proliferators 
activated receptor gamma and are therapeutically used as insulin sensitizers. 2, 4-thiazolidinedione derivatives show variety of 
biological activities such as antibacterial, antifungal, anti-inflammatory, antitumor, anticonvulsant, and cardiotonic besides 
showing promising anti- diabetic activity. 2, 4-thiozolidinedione was synthesized by condensing thiourea with chloroacetic 
acid in the presence of concentrated hydrochloric acid and water. A series of derivatives of 2, 4-thiazolidinedione was prepared 
by mannish reaction by reacting various secondary amines with formaldehyde. In these mannish reaction derivatives of 2, 4-
thiazolidinedione has been used as hydrogen active compounds. The synthesized compounds were characterized by IR, 1H 
NMR and chromatographic method (TLC). The mannish base derivatives of 2, 4-thiazolidinedione were tested for antioxidant 
activity using free radical scavenging activity by DPPH (1, 1-diphenyl-2-picryl-hydrazil) assay method and ascorbic acid was 
used as reference standard. All the tested mannish base derivatives show antioxidant activity but compound ISS-3 and ISS-5 
show promising antioxidant activity concentration at 50µg /ml and can be further studied with modifications. 
Keywords:  2, 4-thiazolidinedione, ascorbic acid, antioxidant activity. 
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CHEMISTRY:                           
 
Thiazolidinediones are five member heterocyclic 
compounds having sulphur,       nitrogen and oxygen atom 
in their ring structure and exhibiting potent as well as wide 
range of pharmacological activities.
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MATERIALS AND METHODS: 
All the chemicals used for synthetic work were purchased 
from CDH and Hamada. Melting points were determined 
in an open capillary tubes and are uncorrected by using 
Veego microprocessor based programmable melting point 
apparatus. The completion of the reaction was routinely 
determined by thin layer chromatography on glass plates 
using silica gel G as absorbent and using chloroform: 
methanol (9:1) solvent system. Spots were visualized by 
iodine chamber. IR spectra were recorded in cm
-1   
using 
KBr pellets on PERKIN ELMER spectrophotometer. 1H 
NMR spectra (δ, ppm) was recorded on BRUKER 
AVANCE II 400 NMR spectrophotometer using DMSO-
d6 or CDCl3 solvent (TMS as internal standard).
 
SCHEME OF SYNTHESIS:
 
Step1- synthesis of 2, 4-thiazolidinedione
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PROCEDURE: 
In a 250ml three-necked flask, a solution containing 56.4g 
(0.6M) of chloroacetic acid in 60ml of water and 45.6g 
(0.6M) of thiourea was dissolved in 60ml of water. The 
mixture was stirred for 15minute till occurrence of white 
precipitates. To the contents of flask was now added 
slowly 60ml of conc. hydrochloric acid from dropping 
funnel to dissolve the precipitates, after which the reaction 
mixture was stirred and refluxed for 10-12hrs at 100-
110˚C, on cooling the contents of flask were solidified to a 
mass of clusters of white needles. The product was filtered 
and washed with water to remove traces of hydrochloric 
acid and dried. It was recrystallised from ethanol, yield 
80%, m.p. (123-125˚C). 
TLC:  chloroform: methanol (9:1) 
RF: 0.62
 
Step 2: Synthesis of various mannish bases derivatives of 2,4-thiazolidinedione 
 
Where: 
R1=R2: 
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PROCEDURE: 
To a solution of 2, 4-thiazolidinedione (0.1M) in DMF, 
formaldehyde (0.2M) was added under stirring. The 
reaction mixture was stirred at room temperature for 0.5hrs 
to complete the reaction of formaldehyde. To the solution 
of secondary amine in DMF was added drop wise and 
reflux for several hrs to complete the reaction. The 
completion of reaction monitored by TLC using solvent 
system chloroform: methanol (9:1). After the completion 
of reaction was poured in an ice cold water and filtered off 
and wash with hot water. Finally it was recrystallised from 
chloroform, ethanol to give final compound.
16 
ANTIOXIDANT ACTIVITY: 
 Free radical scavenging activity by DPPH assays 
method: 
DPPH (1, 1-diphenyl-2-picryl-hydrazil) is stable free 
radical. Methanol solution of DPPH is used to evaluate the 
antioxidant activity of several synthetic compounds. 
Antioxidant on interaction with DPPH, both transfer 
electron or hydrogen atom to DPPH, thus neutralizing its 
free radical character and convert it to1, 1-diphenyl-2-
picryl hydrazine. The degree of discoloration indicates the 
scavenging activity of the drug .The change in absorbance 
produced at 517 nm has been used as measure of its 
antioxidant activity. 
Chemicals used: 
 1,1-diphenyl-2-picryl-hydrazil (DPPH)-Sigma Ltd., 
Ascorbic Acid-Qualigens,  Methanol-Qualigens. 
Preparation of DPPH solution: It was prepared by 
dissolving 33 mg of DPPH in 1 lit. Of methanol just before 
use and kept in dark amber colored bottle to protect from 
sunlight. 
Sample preparation: 
Preparation of stock solution of ligands:  
It was prepared by dissolving 50 mg of ligand in 
100 ml of methanol.  
Standard preparation: 
Preparation of Ascorbic Acid solution: 
It was prepared by dissolving 50 mg of ascorbic 
acid in 100 ml of methanol. 
PROCEDURE: 
A 10, 20,30,40,50 µg/ml concentrations of ligands and 
ascorbic acid were prepared. From this stock solution 1ml 
has been pipette out and 5ml methanol solution of DPPH 
was added ,shaken well and the mixture was incubated at 
37
0
C for 30 minute absorbance of all samples were 
measured against blank at 517 nm.The absorbance of 
DPPH reagent alone was taken as control. The % radical 
scavenging activity can be calculated following formula:
 
%free radical Scavenging activity   =     Absorbance of control - Absorbance of sample     X 100 
Absorbance of control And calculated IC50 value.     
TABLE 1:  DPPH Radical scavenging assay of Compd ISS-1 and Ascorbic acid 
Compd ISS-1 
Conc. 
µg/ml 
Mean Abs   ± 
S.E.M 
% 
Inhibition 
10 1.1233±0.0004 30.9 
20 1.0063±0.0008 38.1 
30 0.9116±0.0014 43.9 
40 0.7110±0.0014 48.1 
50 0.5310±0.0002 56.4 
 
Ascorbic acid 
Conc. 
µg/ml 
Mean Abs   ± 
S.E.M 
         %  
   Inhibition 
10 0.8240±0.0015 49.3 
20 0.7620±0.0022 53.2 
30 0.6830±0.0002 57.9 
40 0.5540±0.005 65.8 
50 0.4810±0.0002 70.2 
 
 
TABLE 2:  DPPH Radical scavenging assay of Compd ISS-2 and Ascorbic acid 
Compd ISS-2 
Conc. 
µg/ml 
Mean Abs   ± 
S.E.M 
% 
Inhibition 
10 1.0200±0.0006 37.20 
20 0.9510±0.0002 41.40 
30 0.8900±0.0002 45.0 
40 0.7500±0.0002 53.80 
50 0.6810±0.0002 58.10 
 
Ascorbic acid 
Conc. 
µg/ml 
Mean Abs   ± 
S.E.M 
         %  
   Inhibition 
10 0.8240±0.0015 49.3 
20 0.7620±0.0022 53.2 
30 0.6830±0.0002 57.9 
40 0.5540±0.005 65.8 
50 0.4810±0.0002 70.2 
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Figure 1:  DPPH Radical scavenging assay of Compd 
ISS-1 and Ascorbic acid 
 
Fig 2:  DPPH Radical scavenging assay of Compd ISS-2 
and Ascorbic acid 
TABLE 3:  DPPH Radical scavenging assay of Compd ISS-3 and Ascorbic acid 
Compd ISS-3 
Conc. 
µg/ml 
Mean Abs   ± 
S.E.M 
% 
Inhibition 
10 0.9813±0.0014 39.6 
20 0.9030±0.0004 44.4 
30 0.8316±0.0014 48.9 
40 0.6810±0.0002 58.1 
50 0.5410±0.0014 66.8 
 
Ascorbic acid 
Conc. 
µg/ml 
Mean Abs   ± 
S.E.M 
% 
Inhibition 
10 0.8240±0.0015 49.3 
20 0.7620±0.0022 53.2 
30 0.6830±0.0002 57.9 
40 0.5540±0.005 65.8 
50 0.4810±0.0002 70.2 
 
 
 
Figure 3:  DPPH Radical scavenging assay of Compd ISS-3 and Ascorbic acid 
TABLE 4: DPPH Radical scavenging assay of Compd ISS-4 and Ascorbic acid 
Compd ISS-4 
Conc. 
µg/ml 
Mean Abs   ± 
S.E.M 
         %  
   Inhibition 
10 1.0116±0.0014 37.80 
20 0.9230±0.0005 43.20 
30 0.8336±0.0014 48.80 
40 0.7813±0.0014 51.80 
50 0.6516±0.0014 59.90 
 
Ascorbic acid 
Conc. 
µg/ml 
Mean Abs   ± 
S.E.M 
         %  
   Inhibition 
10 0.8240±0.0015 49.3 
20 0.7620±0.0022 53.2 
30 0.6830±0.0002 57.9 
40 0.5540±0.005 65.8 
50 0.4810±0.0002 70.2 
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Fig 4:  DPPH Radical scavenging assay of Compd ISS-4 
and Ascorbic acid 
 
Figure 5:  DPPH Radical scavenging assay of Compd 
ISS-5 and Ascorbic acid 
 
TABLE 5:  DPPH Radical scavenging assay of Compd ISS-5 and Ascorbic acid 
Compd ISS-5 
Conc. 
µg/ml 
Mean Abs   ± 
S.E.M 
         %  
   Inhibition 
10 0.9870±0.0002 39.20 
20 0.9116±0.0014 43.9 
30 0.8336±0.0014 48.9 
40 0.7230±0.0005 55.5 
50 0.5616±0.0014 65.50 
 
Ascorbic acid 
Conc. 
µg/ml 
Mean Abs   ± 
S.E.M 
         %  
   Inhibition 
10 0.8240±0.0015 49.3 
20 0.7620±0.0022 53.2 
30 0.6830±0.0002 57.9 
40 0.5540±0.005 65.8 
50 0.4810±0.0002 70.2 
 
 
TABLE 6: Physicochemical data of synthesized compound 
 
REPRESENTATIVE SPECTRAL ANALYSIS: 
3-{(dimethylamino) methyl} thiazolidine-2, 4-dione 
(1SS-1) 
Yield: 49%, m.p.: 120-122˚C,¹H NMR(400 MHZ, DMSO-
d6, δ, ppm), 4.11(s, 2H, COCH2), 4.55(s, 2H, NHCH2), 
2.26(s, 6H, NH(CH3)2), IR Vmax (cm
-1
) (KBr): 1350-1000 
(C-N), 3000-2850 (C-H-str,alk), 1450-1375 (-CH3-bend), 
1465 (-CH2-bend), 1725-1705 (C=O). 
 3-(Morpholinomethyl)thiazolidine-2,4-dione (1SS-
2)Yield:57%, m.p.: 199-201
0
C,¹H NMR(400MHZ, 
DMSO-d6, δ, ppm): 4.11(s, 
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S.No.     R1=R2 Molecular formula  %age yield M.P.* (
o
C) Rf  value 
1. 
 
C6H10N2O2S      49 120-122  0.8 
 
2. 
 
C8H12N2O3S       57  199-201  0.7  
3. 
 
C9H12N2O2S       60  230-233  0.69  
4. 
 
 
C9H14N2 O2S       70 155-158  0.79 
5. 
 
C8H14N2O2 S      60 199-201  0.72 
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2H,COCH2),4.55(s,2H,NHCH2),2.50(t, 4H, CH3-
morpholine ring),3.65(t,4H,CH2-morpholine ring), IR 
Vmax(cm
-1
)(KBr), 1465 (C=O-str), 3150-3050 (-CH2-str),  
3(pyrrolidin-1-ylmethyl) thiazolidine-2, 4-dine (1SS-3) 
CH2-pyrrolidine ring), IR Vmax (cm
-1
) (KBr): 1725-
1705(C=O-str), 1350-1000(CN-str), 3150-3050(CH2-str- 
aro), 3000-2850(CH-str). 
3(piperdin-1-ylmethyl) thiazolidine-2, 4-dione (1SS-4) 
Yield: 70%, m.p.: 155-158˚C,¹H NMR(400MHZ, DMSO-
d6, δ, ppm): 4.11(s, 2H, COCH2), 4.55(s, 2H, NHCH2), 
2.45(t, 4H, CH2-piperidine ring), 1.53(t, 4H, CH2- piper 
dine ring), IR Vmax (cm
-1
)(KBr): 1350-1000(CN str), 1725-
1705(C=O-str), 3150-3050(CH2-str-aro). 
 3((diethyl amino) methyl) thiazloidine-2, 4-dione (1SS-
5) 
Yield: 60%, m.p.: 199-201˚C, ¹H NMR(400MHZ, DMSO-
d6, δ, ppm): 4.11(s, 2H, COCH2), 4.55(s, 2H, NHCH2), 
2.64(q, 4H, NH(CH2)2), 3.65(t, 6H, NH(CH3)2), IR Vmax 
(cm
-1
)(KBr): 1465(CH2-bend), 1450-1375(CH3-bend), 
1725-1705(C=O-str), 1350-1000(CN-str) 
RESULTS AND DISCUSSION: 
The synthesized compounds of 2, 4-thiazloidinedione (Iss-
1 to Iss-5) showed diversified antioxidant activity. A series 
of mannish base of derivatives of 2, 4-thiazolidinedione 
were synthesized by mannish reaction with five different 
secondary amines and formaldehyde. The antioxidant 
activity was evaluated by the free radical scavenging 
activity by using DPPH assay method. In the series of 
mannish base derivatives, compounds Iss-3 and Iss-5 were 
showed significant antioxidant activity.  DPPH (1, 1-
diphenyl-2-picryl-hydrazil) is stable free radical. Methanol 
solution of DPPH is used to evaluate the antioxidant 
activity of several synthetic compounds. Antioxidant on 
interaction with DPPH, both transfer electron on hydrogen 
atom to DPPH, thus neutralizing its free radical character 
and convert it to 1, 1-diphenyl-2-picryl hydrazine. The 
degree of discoloration indicates the scavenging activity of 
the drug. The compound number Iss-1 to Iss-5 show 
promising antioxidant activity at concentrations (10, 20, 
30, 40, and 50µg/ml).  But two (Iss-3 and Iss-5) out of five 
synthesized compounds which were tested by free radical 
scavenging activity by DPPH assay method showed most 
significant antioxidant activity at concentration 50µg /ml.  
CONCLUSION: 
The five compounds were synthesized with the standard 
chemicals and procedure. The compounds were 
characterized through their respective IR, ¹H NMR, UV 
and TLC. The compound number Iss-3 and Iss-5 show 
promising antioxidant activity. 
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